Estrogen patch shortage leaves menopausal women scrambling for relief

Women seeking treatment for perimenopause and menopause are running into a shortage of estrogen patches, one of the most effective options for easing hot flashes and night sweats. The shortage has pushed some patients to call multiple pharmacies, switch brands or formulations, or simply go without treatment while insomnia, brain fog, mood changes and sleep disturbances continue.

The squeeze followed a sharp jump in demand. Epic Research said hormone replacement therapy prescriptions for women ages 50 to 65 rose 86% from the second quarter of 2021 to the fourth quarter of 2025. That rise came after years of lower use tied to the early-2000s Women’s Health Initiative scare and the boxed warnings that long surrounded hormone therapy products. In November 2025, the Food and Drug Administration removed boxed warnings from many hormone therapy products, helping fuel renewed interest in HRT and exposing supply-chain limits that were not built for a rapid rebound.

The shortage has been especially visible in estradiol transdermal systems. The American Society of Health-System Pharmacists lists the shortage as ongoing and says some manufacturers still have supply while others remain constrained. The FDA has said it is aware of the shortage and is coordinating with companies to help boost supply. It also directs patients and providers to its Drug Shortages Database, underscoring that the problem remains active rather than isolated.

For patients, the effect is immediate. Women who depend on patches for symptom control are now competing for a product that can be difficult to locate from one pharmacy to the next. Clinicians say the shortage is particularly disruptive because menopause affects a large and growing population, with more than 1 million U.S. women beginning menopause each year.

The policy shift that widened interest in hormone therapy also showed how fragile the market can be when demand moves faster than manufacturing. Reuters reported on April 9, 2026, that industry sources believed the shortage could take as long as three years to resolve. That timeline points to a deeper imbalance: more patients are returning to evidence-based treatment, but the supply chain for estradiol patches has not caught up, leaving many women to manage symptoms without the therapy that once made relief predictable.